References
- KishiTMatsunagaSOyaKNomuraIIkutaTIwataNMemantine for Alzheimer’s disease: an updated systematic review and meta-analysisJ Alzheimers Dis201760240142528922160
- KishiTMatsunagaSIwataNThe effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: a meta-analysisNeuropsychiatr Dis Treat2017131909192828790827
- NamendaIRNamenda IR (USA) drug package insert Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021487s010s012s014,021627s008lbl.pdf
- NamendaXRNamenda XR (USA) drug package insert Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022525s000lbl.pdf
- AxuraAxura drug package insert Available from: https://www.ema.europa.eu/documents/product-information/axura-epar-product-information_en.pdfAccessed September 5, 2018
- EbixaEbixa drug package insert Available from: https://www.ema.europa.eu/documents/product-information/ebixa-epar-product-information_en.pdfAccessed September 5, 2018
- MemaryMemary (Japan) drug package insert Available from: http://www.info.pmda.go.jp/downfiles/ph/PDF/430574_1190018F1023_1_17.pdf
- BirksJSHarveyRJDonepezil for dementia due to Alzheimer’s diseaseCochrane Database Syst Rev20186CD00119029923184
- BirksJSGrimley EvansJRivastigmine for Alzheimer’s diseaseCochrane Database Syst Rev20154CD001191
- RosenWGMohsRCDavisKLA new rating scale for Alzheimer’s diseaseAm J Psychiatry198414111135613646496779
- Pharmaceuticals and Medical Devices Agency Available from: http://www.pmda.go.jp/drugs/2011/P201100018/43057400_22300AMX00423_K101_2.pdfAccessed September 5, 2018
- PanissetMRoudierMSaxtonJBollerFSevere impairment battery. A neuropsychological test for severely demented patientsArch Neurol199451141458274108
- KitamuraSHommaANakamuraYYoshimuraIPhase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer’s disease – Efficacy, safety and recommended doseJapanese Journal of Geriatric Psychiatry2011224453463
- NakamuraYHommaAKitamuraSYoshimuraIPhase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer’s disease – Efficacy and safetyJapanese Journal of Geriatric Psychiatry2011224464473
- NakamuraYKitamuraSNagakuboTKobayashiMHommaAStudy of Memantine Hydrochloride in Combination with Donepezil Hydrochloride in Patients with Moderate to Severe Alzheimer’s disease – Efficacy and safetyJapanese Journal of Geriatric Medicine2016541111471158
- CummingsJLMegaMGrayKRosenberg-ThompsonSCarusiDAGornbeinJThe Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementiaNeurology19944412230823147991117
- AuerSRMonteiroIMReisbergBThe empirical behavioral pathology in Alzheimer’s disease (E-BEHAVE-AD) rating scaleInt Psychogeriatr1996822472668994895
- The Cochrane CollaborationReview Manager (RevMan) [Computer program] Version 5.3CopenhagenThe Nordic Cochrane Centre2014
- HigginsJPTGreenSCochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 updated March 2011The Cochrane Collaboration2011 Available from: http://handbook.cochrane.org